Serum galectin‐3 level as a marker of thrombogenicity in atrial fibrillation

Koçyiğit, Duygu; Gürses, Kadri Murat; Yalçın, Muhammed Ulvi; Canpınar, Hande; Canpolat, Uğur; Evranos, Banu; Yorgun, Hikmet; Özer, Necla; Güç, Dicle; Aytemir, Kudret

doi:10.1002/jcla.22120

Cited by 12 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This association was further confirmed in another study using delayed enhancement magnetic resonance imaging, which demonstrated an atrial electromechanical delay in PAF patients [35]. Moreover, recent studies showed that increased Gal-3 levels correlated with increased thrombogenicity in persistent AF patients as reflected by reduced LA appendage flow velocity, appendage remodeling, and thrombus formation in transesophageal echocardiography [36, 37]. These findings suggested that baseline Gal-3 levels reflect the risk of stroke in AF patients.…”

Section: Discussionmentioning

confidence: 67%

Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis

Zhang

2019

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Background. Galectin-3 (Gal-3) is involved in fibrosis and heart failure. However, epidemiological studies evaluating the association between Gal-3 and atrial fibrillation (AF) recurrence after catheter ablation showed inconsistent results. We conducted a meta-analysis to comprehensively evaluate the relationship between baseline circulating Gal-3 levels and AF recurrence in patients undergoing catheter ablation. Methods. Relevant studies were identified by systematically searching the PubMed and Embase databases. A random-effect model was used to synthesize the results. Sensitivity analyses, performed by omitting one study at a time, were used to evaluate the robustness of the results. Results. Seven prospective cohort studies including 645 AF patients were included. Within a follow-up duration of up to 18 months, 244 patients developed AF recurrence. Pooled results showed that baseline circulating Gal-3 levels were significantly higher in patients with AF recurrence compared to those without (standardized mean difference: 0.74; 95% confidence interval (CI): 0.21 - 1.27; p = 0.007; I2 = 89%). Moreover, higher baseline Gal-3 levels were independently associated with a significantly higher risk of AF recurrence after catheter ablation (risk ratio: 1.17 per unit of Gal-3; 95% CI: 1.01 - 1.35; p = 0.03; I2 = 40%), which was independent of age, gender, and left atrial dimension. Sensitivity analyses did not significantly affect the results. However, there was a significant publication bias for predicting efficacy of associating preprocedural Gal-3 levels with AF recurrence. Conclusions. Higher preprocedural Gal-3 levels may be associated with increased risk of AF recurrence in patients undergoing catheter ablation.

show abstract

Section: Discussionmentioning

confidence: 67%

Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis

Zhang

2019

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…Furthermore, in patients with AF, high Galectin‐3 levels were closely related to LAA thrombi. Kocyigit et al 21 found that high serum levels of Galectin‐3 predicted the presence of spontaneous atrial echo‐contrast or LAA thrombi. In a subanalysis of the ARISTOTLE study with 1996 AF patients, there was a significant association between Galectin‐3 and mortality 22 .…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, in patients with AF, high Galectin-3 levels were closely related to LAA thrombi. Kocyigit et al 21 found that high serum levels of Galectin-3…”

Section: Gdf-15 and Galectin-3mentioning

confidence: 99%

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE‐17 trial subanalysis

Heřman

Osmančík

Neužil

et al. 2021

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Introduction The randomized PRAGUE‐17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non‐vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. Methods Of 402 patients randomized in the PRAGUE‐17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT‐proBNP, NT‐proANP, Galectin‐3, and GDF‐15 were measured at baseline (before the procedure in the LAAC group), at the 6‐month (and at 24‐month for NT‐proBNP) follow‐up timepoint. Results There were no significant differences in baseline, 6 month, and delta (δ = baseline − 6 month) concentrations of NT‐proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6‐month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6‐month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT‐proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin‐3 and GDF‐15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.

show abstract

“…Gal-3 value was higher in patients with AF than those with sinus rhythm [40]. Gal-3 was also correlated with AF duration and left atrial diameter [41], and significantly higher in the presence of spontaneous echo contrast (SEC) and left atrial thrombus [42].…”

Section: Gal-3 In Atrial Fibrillation (Af)mentioning

confidence: 91%

An overview about galectin-3 and its relationship with cardiovascular diseases

Aşkın¹,

Askin²,

Tanrıverdi³

et al. 2021

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Inflammation is one of the cornerstones of atherosclerosis. Galectin-3 (Gal-3) acts on the stages of the inflammatory process. Gal-3 is a candidate for being a valuable marker for heart failure (HF) and coronary artery disease (CAD). Further studies are needed for the diagnosis and follow-up of CAD. In the literature, the relationship between Gal-3 and CAD has not been researched sufficiently. We aimed to write a review by referring to recent studies about Gal-3 in the etiopathogenesis of CAD, its prognostic significance, and its contribution to the treatment regimen.

show abstract

Serum galectin‐3 level as a marker of thrombogenicity in atrial fibrillation

Abstract: In conclusion, in the setting of persistent AF, serum galectin-3 levels are associated with presence of SEC and LAAFV on TEE. Our findings suggest that serum galectin-3 level may have a place in thromboembolism risk stratification in persistent AF patients.

Cited by 12 publications

References 31 publications

Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis

Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE‐17 trial subanalysis

An overview about galectin-3 and its relationship with cardiovascular diseases

Contact Info

Product

Resources

About